1. Home
  2. LTRN vs SLGL Comparison

LTRN vs SLGL Comparison

Compare LTRN & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

N/A

Current Price

$0.44

Market Cap

10.0M

Sector

Health Care

ML Signal

N/A

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

N/A

Current Price

$54.25

Market Cap

218.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTRN
SLGL
Founded
2013
1997
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
218.9M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
LTRN
SLGL
Price
$0.44
$54.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$17.50
★ $152.50
AVG Volume (30 Days)
★ 227.6K
27.4K
Earning Date
11-24-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.65
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$32.51
52 Week High
$4.34
$97.97

Technical Indicators

Market Signals
Indicator
LTRN
SLGL
Relative Strength Index (RSI) 26.79 30.07
Support Level N/A N/A
Resistance Level $0.84 $81.68
Average True Range (ATR) 0.09 4.34
MACD 0.01 -0.99
Stochastic Oscillator 3.09 11.49

Price Performance

Historical Comparison
LTRN
SLGL

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

Share on Social Networks: